Elemer Piros – Rodman & Renshaw

Rodman & Renshaw

A Rodman & Renshaw analyst with 15 tracked ratings across 15 distinct tickers has a 12.5% success rate on the captured sample, focusing on a mix of sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

1 years ago

2025-03-19 00:00:00+00

Track record

Aggregated

13% success rate

Bullish: 0
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 7
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
BTAI	2025-03-19	buy	$65.00	Aggregated
BTAIBIOXCEL THERAPEUTICS INC	2025-03-19	unknown	$65.00	Aggregated
FBLG	2024-12-12	buy	$12.00	Aggregated
FBLGFIBROBIOLOGICS INC	2024-12-12	unknown	$12.00	Aggregated
THARTHARIMMUNE INC	2024-12-06	unknown	$17.00	Aggregated
QNCX	2024-10-29	buy	$11.00	Aggregated
QNCXQUINCE THERAPEUTICS INC	2024-10-29	unknown	$11.00	Aggregated
MIRA	2024-09-30	buy	$17.00	Aggregated
ATHAATHIRA PHARMA INC	2024-08-19	unknown	$22.00	Aggregated
LONA	2024-08-19	buy	$22.00	Aggregated
ANVS	2024-07-02	buy	$67.00	Aggregated
ANVSANNOVIS BIO INC	2024-07-02	unknown	$67.00	Aggregated
CGTXCOGNITION THERAPEUTICS INC	2024-07-02	unknown	$14.00	Aggregated
ANRO	2024-06-21	buy	$43.00	Aggregated
COYACOYA THERAPEUTICS INC	2024-06-13	unknown	$18.00	Aggregated

Tickers covered(15)

Ticker	Ratings	Last rating	Sources
BTAI	1	2025-03-19	Aggregated
BTAIBIOXCEL THERAPEUTICS INC	1	2025-03-19	Aggregated
FBLG	1	2024-12-12	Aggregated
FBLGFIBROBIOLOGICS INC	1	2024-12-12	Aggregated
THARTHARIMMUNE INC	1	2024-12-06	Aggregated
QNCX	1	2024-10-29	Aggregated
QNCXQUINCE THERAPEUTICS INC	1	2024-10-29	Aggregated
MIRA	1	2024-09-30	Aggregated
ATHAATHIRA PHARMA INC	1	2024-08-19	Aggregated
LONA	1	2024-08-19	Aggregated
ANVS	1	2024-07-02	Aggregated
ANVSANNOVIS BIO INC	1	2024-07-02	Aggregated
CGTXCOGNITION THERAPEUTICS INC	1	2024-07-02	Aggregated
ANRO	1	2024-06-21	Aggregated
COYACOYA THERAPEUTICS INC	1	2024-06-13	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.